ENTOCORT® PRODUCT INFORMATION
(Budesonide controlled ileal release capsules)

NAME OF THE DRUG

The active ingredient in ENTOCORT is budesonide.
The CAS Registry Number for budesonide (11β, 16α) is 51333-22-3.
The Australian Approved Name is budesonide.
The chemical structure for budesonide is

![Chemical structure of budesonide](image)

DESCRIPTION

The active ingredient, budesonide, is a non-halogenated glucocorticoid structurally related to 16α hydroxyprednisolone. The chemical name is 16α,17α-22R, S-propylmethyleneedioxy-pregna-1,4-diene-11β, 21-diol-3, 20-dione.

Budesonide is a white to off-white powder, freely soluble in chloroform, sparingly soluble in ethanol and practically insoluble in water and heptane. Budesonide is a mixture of two epimeric forms, epimer A and epimer B, in a 50:50 ratio. The epimer mixture melts with decomposition between 224°C and 231.5°C.

ENTOCORT is a hard gelatine capsule filled with gastric acid-resistant, prolonged release granules for oral use. The granules are practically insoluble in gastric juice and have prolonged release properties adjusted to release budesonide in the ileum and the ascending colon.

In addition to budesonide, ENTOCORT capsules contain ethylcellulose, tributyl acetylcitrate, methacrylic acid copolymer, triethyl citrate, dimethicone, Polysorbate 80, purified talc and sugar spheres. The capsule shell is made from gelatin, with the colouring agents titanium dioxide and iron oxide.
PHARMACOLOGY

Studies in animals and humans have shown an advantageous ratio between topical anti-inflammatory activity and systemic glucocorticoid effect over a wide dose range. This is explained by the extensive first-pass hepatic degradation of budesonide after systemic absorption, approximately 85 - 90%, in combination with the low potency of formed metabolites. The exact mechanism of action of budesonide in the treatment of Crohn's disease is not fully understood. Anti-inflammatory actions, such as blocking the inflammatory cell influx and inhibition of inflammatory mediator release by inhibition of the arachidonic acid pathway, are probably important. The intrinsic potency of budesonide, measured as affinity to the glucocorticoid receptor, is about 15 times higher than that of prednisolone.

ENTOCORT capsules 9 mg have been shown in clinical pharmacology studies and controlled clinical trials to have equal efficacy, but less effect on the hypothalamus-pituitary-adrenal (HPA) axis and inflammatory markers than prednisolone 40 mg in the treatment of Crohn's disease.

ENTOCORT capsules in studies of up to 8 weeks produced a dose dependent suppression of morning plasma cortisol, on 24-hour plasma cortisol (AUC 0-24 h) and on 24-hour urine cortisol, however, at the recommended dose of 9 mg once daily this effect was significantly less than that seen with prednisolone 20-40 mg daily. ACTH tests have shown that ENTOCORT capsules, compared with prednisolone, have less impact on adrenal function. In one study, adrenal dysfunction, as measured by short ACTH test, was seen in 58% of patients on 9 mg Entocort versus 84% on 40 mg prednisolone. The long-term effect of ENTOCORT capsules on bone density and growth has not been studied in patients with Crohn's disease. In a 5 day study in healthy volunteers, 9 mg and 15 mg doses of Entocort were shown to have a similar suppressant effect on osteocalcin levels as 20 mg prednisolone.

Pharmacokinetic Properties

After oral dosing of plain micronized budesonide, absorption is rapid and seems to be complete. Budesonide is extensively biotransformed by first-pass hepatic degradation (~90% in man) to more polar metabolites of low glucocorticosteroid potency. The glucocorticosteroid activity of the major metabolites, 6β-hydroxybudesonide and 16α-hydroxy-prednisolone, is less than 1% of that of budesonide.

The volume of distribution of budesonide in adult man is approximately 3 L/kg indicating a high tissue affinity. Plasma protein binding averages 85-90% in humans.

Following oral dosing of ENTOCORT capsules 9 mg, taken immediately before breakfast, mean maximum plasma concentration is approximately 5 - 10 nmol/L (C_max) at 3 - 5 hours (T_max). Systemic availability in healthy subjects is approximately 10%, the same as after oral dosing of plain micronized budesonide, which indicates absorption is complete.
While ENTOCORT capsules have equivalent systemic absorption to plain budesonide capsules, it has a longer $T_{\text{max}}$, due to its gastric-acid resistant, prolonged release properties. In a pharmacokinetic study in healthy volunteers, the absorption of budesonide in the targeted area, the ileum and ascending colon, was 58% and 34%, respectively, for ENTOCORT capsules and capsules containing plain budesonide. Terminal ileal and ascending colon absorption in patients with Crohn's disease was more variable (range 3-84%; mean 42.5%).

Following a single dose of ENTOCORT capsules in patients with active Crohn's disease, systemic availability is about 20%. After repeated dosing for 8 weeks, the systemic availability decreases but remains above that seen in healthy subjects.

Elimination of budesonide given as ENTOCORT capsules is rate limited by its absorption, and the terminal half-life averages 4 hours.

**Clinical Trials**

A dose-finding study (n=258) conducted over 12 weeks demonstrated that the lowest effective dose for inducing remission in active ileal or ileocaecal Crohn's disease with budesonide was 9 mg. The recommended dosage of 9 mg once daily has been compared with prednisolone 40 mg for the efficacy of inducing remission in two other studies of equal size (n=176 and 177, respectively). In one study, Entocort was significantly slower at inducing remission with a median time of 29 days to remission compared to 16 days for prednisolone 40 mg. Another study showed Entocort was faster at reaching remission compared to prednisolone, with a median time of 17 days for Entocort 9 mg and 28 days for prednisolone 40 mg. The percentage of patients in remission after 8 weeks' treatment showed no statistically significant differences in either of the two studies. In one study the remission rate in the ENTOCORT group was 52% compared with 65% for prednisolone, while in the other study the remission rate in both groups was 60%. The overall incidence of glucocorticosteroid associated side effects was statistically significantly lower with Entocort. In one study (n=178) the incidence of glucocorticosteroid side effects was 50% for 9 mg Entocort and 59% for 40 mg prednisolone. In another study (n=176) the corresponding figures were 33% for 9 mg Entocort and 55% for 40 mg prednisolone.

No clinical studies have been conducted in children or the elderly.

**INDICATIONS**

ENTOCORT capsules are indicated for the induction of remission in adult patients with mild to moderate Crohn's disease affecting the ileum and/or the ascending colon.

**CONTRAINDICATIONS**

Systemic or local bacterial, fungal or viral infections.

Hypersensitivity to any of the ingredients.
PRECAUTIONS

1. Caution should be taken in patients with tuberculosis, hypertension, diabetes mellitus, osteoporosis, peptic ulcer, glaucoma or cataracts, or with a family history of diabetes or glaucoma, or with any other condition where glucocorticosteroids may have unwanted effects.

2. Chicken pox and measles can have a more serious course in patients on oral glucocorticosteroids. In patients who have not had these diseases, particular care should be taken to avoid exposure. If exposed, therapy with varicella zoster immune globulin (VZIG) or pooled intravenous immunoglobulin (IVIG), as appropriate, may be indicated. If chicken pox develops, treatment with antiviral agents may be considered.

3. As with all glucocorticosteroids, some degree of adrenal suppression may occur in particularly sensitive patients, therefore, monitoring of haematological and adrenal function is strongly advised and patients should be instructed to carry an appropriate warning card.

   In situations where patients are subject to surgery or other stress situations, supplementation with a systemic glucocorticosteroid is recommended.

4. Compromised hepatic function has an influence on the pharmacokinetics of budesonide with a reduced elimination rate and an increased oral systemic availability.

5. During transfer from conventional systemic steroid therapy to ENTOCORT capsules, symptoms related to the change in systemic steroid dose may occur eg. allergic symptoms such as rhinitis and eczema may recur.

6. Particular care is needed in patients who are transferred from systemic glucocorticoid treatment with higher systemic effect to ENTOCORT capsules. These patients may have adrenocortical suppression. Therefore, monitoring of adrenocortical function may be considered in these patients and their dose of systemic steroid should be reduced cautiously.

7. Some patients may feel unwell in a non-specific way during the withdrawal phase, e.g., pain in muscles and joints. A general insufficient glucocorticosteroid effect should be suspected if, in rare cases, symptoms such as tiredness, headache, nausea and vomiting may occur. In these cases a temporary increase in the dose of systemic glucocorticosteroids is sometimes necessary.

8. When Entocort capsules are used chronically in excessive doses, systemic glucocorticosteroid effects such as hypercorticism and adrenal suppression may appear.
Carcinogenicity/Mutagenicity

The carcinogenic potential of budesonide has been evaluated in mouse and rat at oral doses up to 200 and 50 μg/kg/day, respectively. No oncogenic effect was noted in the mouse. One study indicated an increased incidence of brain gliomas in male Sprague-Dawley rats given budesonide, however the results were considered equivocal. Further studies performed in male Sprague-Dawley and Fischer rats showed that the incidence of gliomas in the budesonide-treated rats was low and did not differ from that in the reference glucocorticoid groups or the controls. It has been concluded that treatment with budesonide does not increase the incidence of brain tumours in the rat.

In male rats dosed with 10, 25 and 50 μg/kg/day, those receiving 25 and 50 μg/kg/day showed an increased incidence of primary hepatocellular tumours. This was observed in all three steroid groups (budesonide, prednisolone, triamcinolone acetonide) in a repeat study in male Sprague-Dawley rats thus indicating a class effect of corticosteroids.

The mutagenic potential of budesonide was evaluated in 6 different test systems. No mutagenic or clastogenic effects of budesonide were found.

Gastrointestinal Tolerance

The toxicity of ENTOCORT capsules, with focus on the gastrointestinal tract, has been studied in cynomolgus monkeys in doses up to 5 mg/kg (≥ 25 times the recommended daily dose in man) after repeated oral administration for up to 6 months. No effects were observed in the gastrointestinal tract, either at gross pathology or in the histopathological examination.

Use In Pregnancy Category B3

In animal studies, budesonide was found to cross the placental barrier.

In pregnant animals, administration of budesonide, like other glucocorticosteroids, is associated with abnormalities of fetal development and fetal adrenal suppression. The relevance of this finding to man has not been established. However, as with other drugs the administration of ENTOCORT capsules during pregnancy requires that the benefits for the mother are weighed against the risks for the fetus.

Use In Lactation

Budesonide is excreted in breast milk. Due to the low systemic bioavailability of oral budesonide (see Pharmacokinetic Properties), the amount of drug present in the breast milk is likely to be low, depending on the given dose. However, there are no study data on the use of oral budesonide by nursing mothers or their infants. Therefore, a decision should be made whether to discontinue breastfeeding or to discontinue ENTOCORT, taking into account the clinical importance of ENTOCORT to the mother and the given dose.
Interactions

The metabolism of budesonide is primarily mediated by CYP3A, a subfamily of cytochrome P450. Inhibition of this enzyme can therefore increase systemic exposure of budesonide. During concomitant administration of drugs which are potent CYP3A4 inhibitors (such as ketoconazole), plasma concentrations of budesonide can be significantly higher than observed in patients in clinical trials. As a consequence of this, lower doses of ENTOCORT should be considered.

Cimetidine

The kinetics of budesonide were investigated in healthy subjects with or without cimetidine, 1000 mg daily. After a 4 mg oral dose of budesonide the values of C<sub>max</sub> with and without cimetidine were 5.1 and 3.3 nmol/L. The corresponding values for systemic availability of budesonide were 12 and 10 %, respectively. This indicated a slight inhibitory effect on hepatic metabolism of budesonide, caused by cimetidine. This should be of little clinical importance.

Ketoconazole

The kinetic properties of budesonide were investigated in healthy subjects with or without ketoconazole 200 mg daily. The mean AUC for budesonide was 31.6 nmol.h/L, after administration of ketoconazole for three consecutive days this increased to 238.2 nmol.h/L. The relative systemic availability increased 7 fold. If concomitant treatment of ketoconazole and oral budesonide is indicated, the dose of budesonide should be reduced if systemic glucocorticoid side effects occur.

Grapefruit Juice

The systemic exposure for oral budesonide increases about two times after the intake of grapefruit juice. As with other drugs primarily metabolised through CYP3A, regular ingestion of grapefruit or grapefruit juice should be avoided with budesonide administration.

No other data have been reported regarding interactions between budesonide and other drugs in patients with Crohn’s disease.

Effects on Ability to Drive and Use Machines

There is no information available regarding the effects of ENTOCORT capsules on the ability to drive and use machines.

ADVERSE REACTIONS

ENTOCORT is generally well tolerated. In clinical studies most adverse events were of mild to moderate intensity and of a non-serious character.

Side effects typical of systemic glucocorticosteroids (Cushingoid features), reduced growth velocity and adrenal suppression may occur. These side effects are dependent on dose, treatment time, concomitant and previous glucocorticosteroid intake and individual sensibility.

Data from three controlled clinical trials including Entocort 9 mg (n=268), prednisolone 40 mg (n=145) and placebo (n=66) showed no statistically significant differences in frequency for any adverse events when comparing the Entocort 9 mg group and placebo.
Other Adverse Events that have been recorded with the use of budesonide include muscle cramps, tremor, menstrual disorders, nervousness, blurred vision, skin reactions (urticaria, rash, exanthema), hypokalemia and behavioural changes such as nervousness, insomnia and mood swings. Very rarely anaphylactic reactions have been reported.

Data from the three controlled clinical trials showed statistically that the relative risk of glucocorticosteroid side effects with Entocort 9 mg is reduced compared to prednisolone 40 mg on an overall basis, and in particular with respect to moon face, acne and buffalo hump. The relative risk for glucocorticoid adverse event, particularly occurrence of moon face, was increased relative to placebo.

Long term experience with ENTOCORT capsules is limited. Although not reported during short term trials ENTOCORT capsules, the possible occurrence of adverse effects typical of glucocorticosteroids, such as osteoporosis, diabetes, cataracts must be considered.
DOSAGE AND ADMINISTRATION

The capsules should be swallowed whole with water. The capsules must not be chewed.

Adults
The recommended daily dose for induction of remission is 9 mg, administered once daily in the morning. The dose should be taken before meals.

When treatment with ENTOCORT capsules is to be discontinued, the dose should be tapered over the last 2 to 4 weeks of therapy and not stopped abruptly. The total duration of therapy should be no more than 12 weeks in any single course.

Children
There is presently no experience with ENTOCORT capsules in children.

Elderly
No special dose adjustment is recommended. However, experience with ENTOCORT capsules in the elderly is limited.

OVERDOSAGE

Acute overdosage with ENTOCORT capsules, even in excessive doses, is not expected to be a clinical problem. When used chronically in excessive doses systemic corticosteroid effects such as hypercorticism and adrenal suppression as well as osteoporosis may appear. If such changes occur the dosage of ENTOCORT capsules should be discontinued consistent with accepted procedures for discontinuing prolonged oral therapy with systemic steroids.

PRESENTATION

ENTOCORT 3 mg capsules are two-piece hard gelatin capsules with an opaque light grey body and an opaque pink cap. The capsule is printed CIR 3 mg in black.

Packs of 50, 90 and 100 modified-release capsules are provided in high density polyethylene bottles, with a polypropylene screw cap including a desiccant. The capsules should be dispensed and stored in the original container.

Storage and Shelf-life

ENTOCORT 3 mg capsules: 3 years when stored below 30°C. Replace the cap firmly after use.

NAME AND ADDRESS OF THE SPONSOR

AstraZeneca Pty Ltd
ABN 54 009 682 311
Alma Road
NORTH RYDE NSW 2113
Trade Marks herein are the property of the AstraZeneca group

Date of TGA approval: 14 October 1996
Date of most recent amendment: 29 January 2009